Skip to main content

Table 6 Relationship between of SLC25A5 expression and clinical characteristics of patients with CESC

From: Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification

Gene

Characteristics

Total (N)

Odds ratio (OR)

P value

SLC25A5

Age (≤ 50 vs. > 50)

304

0.802 (0.574–1.109)

0.188

BMI (≤ 25 vs. > 25)

259

1.008 (0.716–1.425)

0.963

Menopause status (Pre vs. Peri and Post)

231

0.900 (0.622–1.295)

0.573

Histological type (adenosquamous vs. squamous cell carcinoma)

304

0.648 (0.430–0.975)

0.037

T stage (T1 and T2 vs. T3 and T4)

241

0.576 (0.327–0.985)

0.050

N stage (N0 vs. N1)

193

1.129 (0.763–1.670)

0.540

M stage (M0 vs. M1)

126

1.515 (0.689–3.164)

0.278

Clinical stage (stage I and stage II vs. stage IV and stage III)

297

0.926 (0.627–1.353)

0.694

Histologic grade (G1 and G2 vs. G4 and G3)

272

0.944 (0.680–1.308)

0.731

Primary therapy outcome (SD and PR and CR vs. PD)

217

1.688 (0.918–3.093)

0.089

Radiation therapy (yes vs. no)

304

1.028 (0.745–1.417)

0.865

  1. Abbreviations: CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, PD progressive disease, CR complete response, SD stable disease, PR partial response, BMI body mass index